Literature DB >> 16714917

Brain injury in the infant: the old, the new, and the uncertain.

Lina Kurdahi Badr Zahr1, Isabell Purdy.   

Abstract

Although neonatal brain injury occurs most frequently after a perinatal hypoxic-ischemic insult, recently studies have noted that variable causes such as metabolic and reperfusion events can result in, or aggravate, a brain insult. Current data suggest that about 2 to 5 of 1,000 live births in the United States and more so in developing countries experience a brain injury Approximately 20% to 40% of infants who survive the brain injury develop significant neurological and developmental impairments. The resulting impact on the child, family, and society presents a formidable challenge to health care professionals. Although several important insights have been gained in the last several years about the epidemiology, diagnosis, and mechanism of brain injury, management remains mostly a cocktail of controversial trials. This article provides a comprehensive review of the pathology, clinical manifestations, and timely management of infants with brain injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714917     DOI: 10.1097/00005237-200604000-00011

Source DB:  PubMed          Journal:  J Perinat Neonatal Nurs        ISSN: 0893-2190            Impact factor:   1.638


  16 in total

Review 1.  Protecting motor networks during perinatal ischemia: the case for delta-opioid receptors.

Authors:  Stephen M Johnson; Sara M F Turner
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

2.  Delta-opioid receptor activation prolongs respiratory motor output during oxygen-glucose deprivation in neonatal rat spinal cord in vitro.

Authors:  S M F Turner; S M Johnson
Journal:  Neuroscience       Date:  2011-05-06       Impact factor: 3.590

3.  cGAS/STING Pathway Activation Contributes to Delayed Neurodegeneration in Neonatal Hypoxia-Ischemia Rat Model: Possible Involvement of LINE-1.

Authors:  Marcin Gamdzyk; Desislava Met Doycheva; Camila Araujo; Umut Ocak; Yujie Luo; Jiping Tang; John H Zhang
Journal:  Mol Neurobiol       Date:  2020-04-06       Impact factor: 5.590

4.  Pharmacological neuroprotection after perinatal hypoxic-ischemic brain injury.

Authors:  Xiyong Fan; Annemieke Kavelaars; Cobi J Heijnen; Floris Groenendaal; Frank van Bel
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

5.  Statistical versus clinical significance for infants with brain injury: reanalysis of outcome data from a randomized controlled study.

Authors: 
Journal:  Clin Nurs Res       Date:  2009-03-10       Impact factor: 2.075

Review 6.  The endogenous regenerative capacity of the damaged newborn brain: boosting neurogenesis with mesenchymal stem cell treatment.

Authors:  Vanessa Donega; Cindy T J van Velthoven; Cora H Nijboer; Annemieke Kavelaars; Cobi J Heijnen
Journal:  J Cereb Blood Flow Metab       Date:  2013-02-13       Impact factor: 6.200

7.  Importance of schedule of administration in the therapeutic efficacy of guanosine: early intervention after injury enhances glutamate uptake in model of hypoxia-ischemia.

Authors:  M B Moretto; B Boff; D Lavinsky; C A Netto; J B T Rocha; D O Souza; S T Wofchuk
Journal:  J Mol Neurosci       Date:  2008-10-10       Impact factor: 3.444

Review 8.  Effect of environmental enrichment on behavioral and morphological outcomes following neonatal hypoxia-ischemia in rodent models: A systematic review and meta-analysis.

Authors:  L E Durán-Carabali; F K Odorcyk; E F Sanches; M M de Mattos; F Anschau; C A Netto
Journal:  Mol Neurobiol       Date:  2022-01-17       Impact factor: 5.590

9.  Neuroprotective therapies after perinatal hypoxic-ischemic brain injury.

Authors:  Felipe Goñi de Cerio; Idoia Lara-Celador; Antonia Alvarez; Enrique Hilario
Journal:  Brain Sci       Date:  2013-03-05

10.  Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury.

Authors:  I Lara-Celador; F Goñi-de-Cerio; Antonia Alvarez; Enrique Hilario
Journal:  Neural Regen Res       Date:  2013-03-15       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.